L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7345-7351

  Li, Shengjin ^a,e   Jo, Young Suk ^b   Lee, Jae Hyek ^d   Min, Jeong Ki ^c   Lee, Eung Seuk ^c   Park, Taewoo ^c   Kim, Jin Man ^a   Hong, Hyo Jeong ^c  

^a Chungnam National University   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Yonsei University College of Dentistry   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; CELL ADHESION MOLECULE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEURAL CELL ADHESION MOLECULE L1; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 73149113591     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0959     Document Type: Article

References (45)

1. Roberts SK, Ludwig J, Larusso NF. The pathobiology of biliary epithelia. Gastroenterology 1997;112:269-79.
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14.
3. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-73.
4. Shiojiri N. Development andd ifferentiation of bile ducts in the mammalian liver. Microsc Res Tech 1997;39:328-35.
5. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic andextrahepatic cholangiocarcinoma: a hospital-basedc ase-control study. Am J Gastroenterol 2007;102:1016-21.
6. Brummendorf T, Rathjen FG. Axonal glycoproteins with immunoglobulin- andfibronectin type III-relatedd omains in vertebrates: structural features, binding activities, and signal transduction. J Neurochem 1993;61:1207-19.
7. Hortsch M. The L1 family of neural cell adhesion molecules: oldp roteins performing new tricks. Neuron 1996;17:587-93.
8. Lindner J, Rathjen FG, Schachner M. L1 mono- and polyclonal antibodies modify cell migration in early postnatal mouse cerebellum. Nature 1983;305:427-30.
9. Asou H, Miura M, Kobayashi M, Uyemura K. The cell adhesion molecule L1 has a specific role in neural cell migration. Neuroreport 1992;3:481-4.
10. Dahme M, Bartsch U, Martini R, Anliker B, Schachner M, Mantei N. Disruption of the mouse L1 gene leads to malformations of the nervous system. Nat Genet 1997;17:346-9.
11. Demyanenko GP, Tsai AY, Maness PF. Abnormalities in neuronal process extension, hippocampal development, and the ventricular system of L1 knockout mice. J Neurosci 1999;19:4907-20.
12. Thor G, Probstmeier R, Schachner M. Characterization of the cell adhesion molecules L1, N-CAM andJ1 in the mouse intestine. EMBO J 1987;6:2581-6.
13. Ebeling O, Duczmal A, Aigner S, et al. L1 adhesion molecule on human lymphocytes and monocytes: expression andinvolvement in binding to αvβ3 integrin. Eur J Immunol 1996;26:2508-16.
14. Pancook JD, ReisfeldRA , Varki N, Vitiello A, Fox RI, Montgomery AM. Expression andregulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic andlym phoid origin. J Immunol 1997;158:4413-21.
15. Debiec H, Christensen EI, Ronco PM. The cell adhesion molecule L1 is developmentally regulatedin the renal epithelium and is involvedin kidney branching morphogenesis. J Cell Biol 1998;143:2067-79.
16. Izumoto S, Ohnishi T, Arita N, Hiraga S, Taki T, Hayakawa T. Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion. Cancer Res 1996;56:1440-4.
17. Hoefnagel CA, Rutgers M, Buitenhuis CK, et al. A comparison of targeting of neuroblastomawith mIBG andanti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med2001;28:359 -68.
18. Thies A, Schachner M, Moll I, et al. Overexpression of the cell adhesion molecule L1 is associatedwith metastasis in cutaneous malignant melanoma. Eur J Cancer 2002;38:1708-16.
19. Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in patients with uterine andovarian carcinomas. Lancet 2003;362:869-75.
20. Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res 2005;11:1190-7.
21. Talantov D, Mazumder A, Yu JX, et al. Novel genes associatedwith malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005;11:7234-42.
22. Gavert N, Conacci-Sorrell M, Gast D, et al. L1, a novel target of β-catenin signaling, transforms cells andis expressedat the invasive front of colon cancers. J Cell Biol 2005;168:633-42.
23. Kaifi JT, Zinnkann U, Yekebas EF, et al. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J Gastroenterol 2006;12:94-8.
24. Boo YJ, Park JM, Kim J, et al. L1 expression as a marker for poor prognosis, tumor progression, andshort survival in patients with colorectal cancer. Ann Surg Oncol 2007;14:1703-11.
25. Kaifi JT, Reichelt U, Quaas A, et al. L1 is associatedw ith micrometastatic spread andpoor outcome in colorectal cancer. ModPathol 2007;20:1183-90.
26. Sebens Muerkoster S, Werbing V, Sipos B, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007;26:2759-68.
27. Zecchini S, Bianchi M, Colombo N, et al. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008;68:1110-8.
28. Kim HS, Yi SY, Jun HJ, et al. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. APMIS 2009;117:140-6.
29. Ku J-L, Yoon K-A, Kim I-J, et al. Establishment andcharacter ization of six human biliary tract cancer cell lines. Br J Cancer 2002;87:187-93.
30. Homma S, Nagamori S, Fujise K, et al. Human bile duct carcinoma cell line producing abundant mucin in vitro. Gastroenterol Jpn 1987;22:474-9.
31. Tamada S, Shibahara H, Higashi M, et al. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 2006;12:4257-64.
32. Shimizu Y, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. The morbidity, mortality, andprognostic factors for ampullary carcinoma andd istal cholangiocarcinoma. Hepatogastroenterology 2008;55:699-703.
33. Shirai K, Ebata T, Oda K, Nishio H, Nagasaka T, Nimura Y. Perineural invasion is a prognostic factor in intrahepatic cholangiocarcinoma. WorldJ Surg 2008;32:2395-402.
34. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl AcadSci U S A 1999;96:5522-7.
35. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
36. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-8.
37. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the β-catenin/LEF-1 pathway in melanoma andcolon cancer and its expression enhances motility andconfers tumorigenesis. Genes Dev 2002;16:2058-72.
38. Sugimachi K, Taguchi K, Aishima S, et al. Alterede xpression of β-catenin without genetic mutation in intrahepatic cholangiocarcinoma. ModPathol 2001;14:900-5.
39. Lim K, Han C, Xu L, Isse K, Demetris AJ, Wu T. Cyclooxygenase-2-derived prostaglandin E2 activates β-catenin in human cholangiocarcinoma cells: evidence for inhibition of these signaling pathways by ω3 polyunsaturatedf atty acids. Cancer Res 2008;68:553-60.
40. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological andp rognostic significance of EGFR, VEGF, andHER2 expression in cholangiocarcinoma. Br J Cancer 2008;98:418-25.
41. Raveh S, Gavert N, Ben-Ze'ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett 2009;282:137-45.
42. Thelen K, Kedar V, Panicker AK, Schmid RS, Midkiff BR, Maness PF. The neural cell adhesion molecule L1 potentiates integrin-dependent cell migration to extracellular matrix proteins. J Neurosci 2002;22:4918-31.
43. Mechtersheimer S, Gutwein P, Agmon-Levin N, et al. Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. J Cell Biol 2001;155:661-73.
44. Gutwein P, Stoeck A, Riedle S, et al. Cleavage of L1 in exosomes andapoptotic membrane vesicles releasedfrom ovarian carcinoma cells. Clin Cancer Res 2005;11:2492-501.
45. Arlt MJ, Novak-Hofer I, Gast D, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006;66:936-43.